Genentech parent Roche has shaved one of five projects from its drug portfolio since Q3 2023. Here’s what that means for the ...

NovelMed has received ODD status from the US FDA for NM5072 for treating paroxysmal nocturnal hemoglobinuria (PNH).

This came after AstraZeneca Pharma presented the proposal for a grant of permission to import and market Eculizumab ...

Here are seven pharmaceutical stocks to buy with dividends of at least 2%, according to Bank of America: ...

Discover how BioCryst Pharmaceuticals' patent for complement system inhibitors offers groundbreaking treatment options for various diseases.

Hemolysis is the process of red blood cell (RBC) breakdown. Normally, your body makes new RBCs to replace those that have ...

Johnson & Johnson, Roche, and AstraZeneca are set to become the top 3 orphan drugmakers by sales ...

Let's consider two in the healthcare sector: Bristol Myers Squibb (NYSE: BMY) and Novartis (NYSE: NVS). These drugmakers have ...

Novartis on Monday shared late-stage data for its potential multibillion-dollar drug Fabhalta, in what the company contends ...

Analyst Douglas Tsao of H.C. Wainwright maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report), retaining the price ...

Novartis' key drugs like Fabhalta and Cosentyx may drive short-term growth, offsetting potential losses from generic ...

U.K.-based biotech Adaptimmune Therapeutics announced the termination of a multi-year strategic collaboration it struck with ...